Protalix BioTherapeutics to Review CHMP Opinion for ELELYSO Conference Call and Webcast Scheduled for Friday, June 22 at 9:00

Protalix BioTherapeutics to Review CHMP Opinion for ELELYSO

Conference Call and Webcast Scheduled for Friday, June 22 at 9:00 AM EDT

CARMIEL, Israel, June 22, 2012/GlobeNewswire/Protalix BioTherapeutics,

Inc. (NYSE-MKT:PLX, TASE:PLX), announced today the Company has scheduled a conference call and webcast for Friday, June 22,

2012 at 9:00 AM EDT to review the Committee for Medicinal Products for Human Use's (CHMP) opinion for taliglucerase

alfa (ELELYSO ), an enzyme replacement therapy for the treatment of Gaucher disease.

To participate in the conference call,

please dial +1 (877) 868-1833 (toll free from the U.S. and Canada), or +1 (914) 495-8604 (for international callers); Conference

ID 93586245. Investors may also access a live audio webcast of this conference call at www.protalix.com

on the event calendar page. A replay of this conference call and webcast will be available approximately two hours after the conclusion

of the call and will remain available for 14 days. The audio replay can be accessed by dialing +1 (855) 859-2056 (toll free from

the U.S. and Canada), or +1 (404) 537-3406 (for international callers) and entering Conference ID 93586245.

Protalix is a biopharmaceutical company focused on the development

and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system,

ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective,

industrial-scale manner. Protalix's first approved product manufactured by ProCellEx, ELELYSO (taliglucerase alfa), was

approved for marketing by the U.S. Food and Drug Administration on May 1, 2012 and is partnered with Pfizer for worldwide development

and commercialization, excluding Israel, where Protalix retains full rights. Marketing applications for taliglucerase alfa have

been filed in additional territories as well. Protalix's development pipeline also includes the following product candidates: PRX-102,

a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant

human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based

pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for

the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel(R)) for the treatment of certain

immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque

psoriasis; and others.

Forward Looking Statements

To the extent that statements in this press release are not

strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private

Securities Litigation Reform Act of 1995. The terms "anticipate," "believe," "estimate," "expect"

and "intend" and other words or phrases of similar import are intended to identify forward-looking statements. These

forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and

results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to

such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause material differences

include, among others: risks relating to delays in the European Medicines Agency's (EMA) or other foreign regulatory authorities'

approval of any applications we file or refusals to approve such filings, including the filings made regarding taliglucerase alfa

for the treatment of Gaucher disease; the risk that applicable regulatory authorities may refuse to approve the marketing and sale

of a drug product even after acceptance of an application we file for the drug product; and other factors described in our filings

with the Securities and Exchange Commission. The statements in this release are valid only as of the date hereof and we disclaim

any obligation to update this information.

The Trout Group, LLC

Jennifer Conrad or Kari Watson

MacDougall Biomedical Communications